The effect of coronary artery disease on the prognosis of hypertrophic cardiomyopathy: a multi-center cohort study

Author:

Liao Qian1,Deng Xiaodan2,Ma Huihui1,Shu Yan1,Zeng Shengzhi3,zhou Yongmei4,Luo Liangjun5,Zhao Gang6,He Tao4,Liu Mingjiang1,Tao Jianhong1,Hua Wei7,Li Xiaoping1

Affiliation:

1. Department of Cardiology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China

2. Wenjiang Hospital of Sichuan Provincial People’s Hospital

3. Department of Cardiology, Guanghan People's Hospital

4. Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

5. Clinical lab, The First People's Hospital of Liangshan Yi Autonomous Prefecture

6. Department of Cardiology, The First People's Hospital of Liangshan Yi Autonomous Prefecture

7. Department of Clinical Electrophysiology, Fuwai Hospital and Cardiovascular Institute, Chinese Academy of Medical Science and Peking Union Medical College

Abstract

Abstract Background: There is a paucity of patients with hypertrophic cardiomyopathy (HCM) developed coronary artery disease (CAD), and the impact of CAD on the prognosis of HCM patients is unknown. Therefore, our real-world cohort study aimed to investigate prognosis of CAD in patients with HCM. Methods: A cohort study was undertaken in HCM patients from May 2003 to September 2021. A total of 2268 patients were enrolled, with a mean follow-up of 5.6 years (interquartile range 2.4-8.4 years). Outcome assessment was based on the all-cause mortality, cardiovascular mortality/cardiac transplantation and SCD. Results: Among the 2268 patients studied, 353(15.6%) died during a mean follow-up of 5.6 years. The patients were divided into CAD (n=504) and non-CAD (n=1764) groups. No difference in the all-cause mortality, cardiovascular mortality/cardiac transplantation or SCD between patients with CAD and no CAD (log-rank c2=0.201, P=0.654; log-rank c2=0.233, P=0.629; log-rank c2=1.523, P=0.217). In the Cox analysis, CAD was not a significant independent predictor of all-cause mortality, cardiovascular mortality/cardiac transplantation or SCD in patients with HCM. Conclusion: In conclusion, there was no significant differences in mortality between the HCM patients with and without CAD, indicating no effect of CAD on all-cause mortality, cardiovascular mortality/cardiac transplantation, and SCD in the present large-scale study.

Publisher

Research Square Platform LLC

Reference20 articles.

1. The pathology of hypertrophic cardiomyopathy;Hughes SE;Histopathology,2004

2. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies;Richardson P;Circulation,1996

3. Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario;Weissler-Snir A;Circulation,2019

4. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC);Elliott PM;Eur Heart J,2014

5. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen SR;Circulation,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3